Every material Form 8-K West Pharmaceutical Services filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
West Pharmaceutical Services reported third-quarter 2025 net sales of $804.6 million, up 7.7% from a year earlier, and diluted EPS of $1.92 versus $1.85. The company raised its full-year 2025 net sales guidance to $3.060 billion to $3.070 billion and adjusted-diluted EPS guidance to $7.06 to $7.11, and it introduced fourth-quarter guidance that is below the third-quarter level.
Q3 net sales $804.6 million (up 7.7%, organic up 5.0%); HVP Components rose 16.3% to $390.0 million
Q3 diluted EPS $1.92 vs. $1.85; adjusted-diluted EPS $1.96 vs. $1.85 a year earlier
Full-year 2025 adjusted-diluted EPS guidance raised to $7.06 to $7.11, from $6.65 to $6.85
Fourth-quarter 2025 net sales guidance of $790 million to $800 million and adjusted-diluted EPS guidance of $1.81 to $1.86
West Pharmaceutical Services said Senior Vice President, General Counsel and Corporate Secretary Kimberly Banks MacKay will leave the company. The company and Ms. MacKay have agreed to a transition period ending no later than December 31, 2025, and she will continue her current duties until she departs.
Kimberly Banks MacKay, SVP, General Counsel and Corporate Secretary, is leaving the company.
Transition period to end no later than December 31, 2025, to ensure continuity of responsibilities.
Ms. MacKay will continue her current duties until her departure.
Filing does not name a successor or give financial terms of the departure.
West Pharmaceutical Services reported second-quarter 2025 net sales of $766.5 million, up 9.2%, with diluted EPS of $1.82 versus $1.51 a year earlier. The company raised its full-year 2025 net sales guidance to $3.040 billion to $3.060 billion and its adjusted-diluted EPS guidance to $6.65 to $6.85, both up from prior ranges.
Q2 2025 net sales of $766.5 million rose 9.2%; organic net sales grew 6.8%.
Adjusted-diluted EPS was $1.84, compared with $1.52 in the second quarter of 2024.
Full-year 2025 adjusted-diluted EPS guidance rose to $6.65 to $6.85 from $6.15 to $6.35.
Board approved a fourth-quarter 2025 dividend of $0.22 per share, payable November 19, 2025 to holders of record as of November 12, 2025.
West Pharmaceutical Services appointed Robert McMahon, formerly CFO of Agilent Technologies, as Senior Vice President and Chief Financial Officer effective August 4, 2025, succeeding Bernard Birkett, who is retiring and will serve as Senior Advisor to the CEO through December 31, 2025. The filing discloses pay terms including an $800,000 base salary, a $3,115,000 sign-on bonus and a $4,200,000 replacement equity grant, which matter to shareholders as a change in the company's top finance role and a related compensation cost.
Robert McMahon becomes SVP and CFO effective August 4, 2025, overseeing finance, audit, treasury, tax, investor relations and procurement.
Offer terms include an $800,000 initial base salary and an annual bonus target of 80% of base salary.
One-time cash sign-on bonus of $3,115,000 and a replacement equity grant with a grant date fair value of $4,200,000.
LTI award with grant date fair value of $3,000,000 is scheduled for August 11, 2025.
West Pharmaceutical Services said CFO Bernard Birkett intends to retire later this year and will stay until a successor is found, then advise through December 31, 2025. The company also named Shane Campbell, formerly of Carlisle Companies, as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025, with a $600,000 base salary.
Bernard Birkett notified the company on April 22, 2025 of his intention to retire as SVP and CFO later this year; a search for a successor has started
Birkett will remain in his role until a successor is found, then serve in an advisory role until December 31, 2025
Shane Campbell joins May 5, 2025 with a $600,000 base salary, a 75% target bonus, a $1,000,000 LTI grant and a $400,000 sign-on RSU award
Campbell previously was Chief Commercial Officer of Carlisle Companies' Construction Materials business and spent 20 years at DuPont
West Pharmaceutical Services reported first-quarter 2025 net sales of $698.0 million, up 0.4%, but adjusted-diluted EPS fell to $1.45 from $1.56 a year earlier. The company raised its full-year 2025 net sales and adjusted-diluted EPS guidance and declared a third-quarter dividend of $0.21 per share, so shareholders see higher expected results for the year alongside weaker first-quarter profit.
Q1 2025 net sales were $698.0 million, up 0.4%; organic net sales grew 2.1%.
Reported-diluted EPS was $1.23 versus $1.55 a year earlier; adjusted-diluted EPS was $1.45 versus $1.56.
Full-year 2025 net sales guidance rose to $2.945 billion-$2.975 billion from $2.875 billion-$2.905 billion.
Full-year 2025 adjusted-diluted EPS guidance rose to $6.15-$6.35 from $6.00-$6.20; the guidance includes an estimate of $20 million to $25 million in tariff costs.
West Pharmaceutical Services disclosed that Cindy Reiss-Clark, its former Senior Vice President and Chief Commercial Officer and a named executive officer, left the company effective March 7, 2025. She signed a Separation Agreement and Release dated April 9, 2025, which provides one year of salary continuation and other benefits in exchange for a release of claims and continued restrictive covenants.
Departure effective March 7, 2025; role was Senior Vice President and Chief Commercial Officer
Salary continuation for one year at a salary of $489,500, plus continued welfare benefits
2025 payment of $57,526 for pro-rated Annual Incentive Plan target; outplacement services up to $15,000
West Pharmaceutical Services said Chief Commercial Officer Cindy Reiss-Clark left the company effective March 7, 2025. Aileen Kinsella, Head of Proprietary Product Sales, will manage the role's responsibilities on an interim basis, and the filing does not name a permanent successor.
Departure of Senior Vice President and Chief Commercial Officer Cindy Reiss-Clark, effective March 7, 2025
Aileen Kinsella, Head of Proprietary Product Sales, will manage leadership responsibilities on an interim basis
Filing does not state reasons for the departure or name a permanent replacement
Company announced the departure on March 7, 2025; the 8-K was filed March 11, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every West Pharmaceutical Services filing is on SEC EDGAR ↗. 8-K briefs of other companies →